GRI Stock Analysis: Buy, Sell, or Hold?
GRI - GRI Bio, Inc. Common Stock
$2.26
-0.02 (-0.88%)
▼
5d:
-12.74%
30d:
-11.37%
90d:
+718.84%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 21, 2026
Get Alerted When GRI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GRI is down 12.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GRI is down 12.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GRI is currently trading at $2.26, which is considered oversold relative to its 30-day fair value range of $2.34 to $2.68.
Technical Outlook: Technically, GRI is in a uptrend. The price is currently testing key support at $2.22. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $160.00 (+6979.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GRI is in a uptrend. The price is currently testing key support at $2.22. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $160.00 (+6979.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.34 -
$2.68
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 6979.6% below Wall St target ($160.00)
- WARNING: Recommendation downgraded due to -12.7% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$2.34 -
$2.68
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$2.22
Resistance Level
$2.75
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.28
Wall Street Target
$160.00
(+6979.6%)
Share & Embed Analysis
Last updated: March 30, 2026 6:32 PM ET
Data refreshes hourly during market hours. Next update: 7:32 PM
Data refreshes hourly during market hours. Next update: 7:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRI showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 53 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$134 | 59 HOLD |
|
EXEL
Exelixis Inc |
BUY
20 analysts |
$47 | 62 BUY |
